Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04753216 · ClinicalTrials.gov registry record · Phase 2

Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Phase 2 study, sponsored by Northwestern University.

Completed
Registry status
Phase 2
Development phase
3
Enrollment target

NCT04753216: Completed Phase 2 study, sponsored by Northwestern University.

NCT04753216 is a Phase 2 study that has completed, run by Northwestern University. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04753216, a Phase 2 study, has completed, sponsored by Northwestern University.

COMPLETED
Registry status
Phase 2
Development phase
3 participants
Enrollment target

Study Summary

This phase II trial investigates the effect of irinotecan liposome and bevacizumab in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that shows less response to platinum therapy (platinum resistant), has come back (recurrent), or does not respond to treatment (refractory). Irinotecan liposome may help block the formation of growths that may become cancer. Bevacizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Giving irinotecan liposome and bevacizumab may kill more cancer cells.

Primary Outcome

Defined as the proportion of treated subjects who experience an objective response, confirmed complete response (CR) or confirmed partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Complete Response (CR) = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR) = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the

Interventions

  • BIOLOGICAL Bevacizumab
  • DRUG Irinotecan Sucrosofate

Trial Details

FieldValue
Enrollment Target 3 participants
Start Date 2021-03-16
Est. Completion 2021-10-25
Phase Phase 2
Northwestern University

1,209 total trials

What the finished NCT04753216 record still lists

NCT04753216 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.

NCT04753216 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04753216 about?

NCT04753216 is a clinical study titled "Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". This phase II trial investigates the effect of irinotecan liposome and bevacizumab in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that shows less response to platinum therapy (platinum resistant), has come back (recurrent), or does not respond to treatment (refractor...

What is the current status of trial NCT04753216?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2021-03-16. Estimated completion is 2021-10-25.

What interventions are being tested in trial NCT04753216?

The interventions under investigation include: Bevacizumab (BIOLOGICAL), Irinotecan Sucrosofate (DRUG).

Who is sponsoring clinical trial NCT04753216?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Learn More About Clinical Trials

How this trial's enrollment target compares

Where NCT04753216's enrollment target sits among peer trials

3 2001st of 2000 the lowest of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04753216, the US trial registry maintained by the National Library of Medicine. NCT04753216 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.